New drugs: ambrisentan, temsirolimus, and eculizumab.
Hussar
Daniel A
DA
Philadelphia College of Pharmacy, University of the Science in Philadelphia, Philadelphia, PA, USA.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006401:Hematologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006457:Hemoglobinuria, Paroxysmal / Q000188:drug therapy; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy; D009965:Orphan Drug Production; D010666:Phenylpropionates / Q000009:adverse effects / Q000627:therapeutic use*; D011724:Pyridazines / Q000009:adverse effects / Q000627:therapeutic use*; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000959:Antihypertensive Agents; D000970:Antineoplastic Agents; D006401:Hematologic Agents; D010666:Phenylpropionates; D011724:Pyridazines; C401859:temsirolimus; C481642:eculizumab; C467894:ambrisentan; D020123:Sirolimus